Halozyme Therapeutics Balance Sheet Health
Financial Health criteria checks 3/6
Halozyme Therapeutics has a total shareholder equity of $83.8M and total debt of $1.5B, which brings its debt-to-equity ratio to 1788.9%. Its total assets and total liabilities are $1.7B and $1.6B respectively. Halozyme Therapeutics's EBIT is $340.1M making its interest coverage ratio 38.8. It has cash and short-term investments of $336.0M.
Key information
1,788.9%
Debt to equity ratio
US$1.50b
Debt
Interest coverage ratio | 38.8x |
Cash | US$336.00m |
Equity | US$83.81m |
Total liabilities | US$1.65b |
Total assets | US$1.73b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 0J2O's short term assets ($746.4M) exceed its short term liabilities ($112.5M).
Long Term Liabilities: 0J2O's short term assets ($746.4M) do not cover its long term liabilities ($1.5B).
Debt to Equity History and Analysis
Debt Level: 0J2O's net debt to equity ratio (1388%) is considered high.
Reducing Debt: 0J2O's debt to equity ratio has increased from 50.8% to 1788.9% over the past 5 years.
Debt Coverage: 0J2O's debt is well covered by operating cash flow (25.9%).
Interest Coverage: 0J2O's interest payments on its debt are well covered by EBIT (38.8x coverage).